Loading...

ACRS ACLARIS THERAPEUTICS INC Investments/Divestments 8-K Filing

CLRS

CRS

ACLARIS THERAPEUTICS INC

(ACRS)

2024 8-K

Summary

Summary

R&D Day Announcement

Financial Statements

Clinical Trials

Investor Meetings

Increase in authorized shares

Financial Statements

Financial Results

Corporate Update

Licensing and Funding

Financial Results

Financial Results Announcement

Agreement with OMERS

Annual Meeting Results

Departure of Directors

Financial Results Announcement

Amendment to Filing

Management Changes

Financial Results and Manag...

Workforce Reduction

Conference Call and Press R...

Financial Results Announcement

Phase 1 trial results

Financial Results Announcement

Amended Employment Agreement

Annual Meeting Results

Lease Agreement

Amendment to Consulting Ser...

Clinical Trial Results

Sales Agreement and Termina...

Financial Results Announcement

Presentation at Investor Co...

Employment Agreements

External Links:

Aclaris Therapeutics entered into a royalty purchase agreement with OMERS, selling a portion of its future royalty payments and milestones for OLUMIANT to OMERS for $26.5 million upfront and up to an additional $5.0 million based on sales milestones in 2024.

AI Assistant

ACLARIS THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.